Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAMP trial in recent-onset juvenile idiopathic arthritis
2014-003260-20Phase 4Completed
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of methotrexate, 5-aminosalicylic acid + sulphasalazine and hydroxychloroquine in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Inactive disease at 6 months. Started Nov 2015; status: completed.
02
Drugs
methotrexate5-aminosalicylic acid + sulphasalazinehydroxychloroquine
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2014-003260-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003260-20.